Cargando…
Radotinib Induces Apoptosis of CD11b(+) Cells Differentiated from Acute Myeloid Leukemia Cells
Radotinib, developed as a BCR/ABL tyrosine kinase inhibitor (TKI), is approved for the second-line treatment of chronic myeloid leukemia (CML) in South Korea. However, therapeutic effects of radotinib in acute myeloid leukemia (AML) are unknown. In the present study, we demonstrate that radotinib si...
Autores principales: | Heo, Sook-Kyoung, Noh, Eui-Kyu, Yoon, Dong-Joon, Jo, Jae-Cheol, Choi, Yunsuk, Koh, SuJin, Baek, Jin Ho, Park, Jae-Hoo, Min, Young Joo, Kim, Hawk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466365/ https://www.ncbi.nlm.nih.gov/pubmed/26065685 http://dx.doi.org/10.1371/journal.pone.0129853 |
Ejemplares similares
-
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2017) -
Author Correction: Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2021) -
Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling
por: Heo, Sook-Kyoung, et al.
Publicado: (2022) -
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2020) -
The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway
por: Heo, Sook-Kyoung, et al.
Publicado: (2021)